Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPER BRAIN
NCT05807893Phase 3Completed
- Sponsor
- Sun Yat-sen University
- Start
- May 2023
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in non-small cell lung cancer (NSCLC), brain metastases, sponsored by Sun Yat-sen University. Started May 2023; status: completed.
02
Drugs
serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT05807893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05807893.